SIC-19
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib ), as well as in ovarian cancer organoids and xenograft models[1].
Product Specifications
CAS Number
713112-69-7
UNSPSC
12352005
Target
Salt-inducible Kinase (SIK)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sic-19.html
Purity
98.0
Solubility
DMSO : 2.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=C(C(NNC(NC(C2=CC=CC=C2)=O)=S)=O)C(C3=CC=C(OC)C(OC)=C3)=C(C)S1)C4=CC=CC=C4
Molecular Formula
C29H26N4O5S2
Molecular Weight
574.67
References & Citations
[1]Wang F, et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat. 2024 May;74:101077.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SIK2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RC222676L3V 200 µL
KRTHA2 (KRT32) (NM_002278) Human Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details